US cost–effectiveness analysis of apixaban compared with warfarin, dabigatran and rivaroxaban for nonvalvular atrial fibrillation, focusing on equal value of life years and health... by Nipun Atreja, Kasper Johannesen, Rupesh Subash, Carina Bektur, Melissa Hagan, Dionne M Hines, Iulia Dunnett, Ewa Stawowczyk